SMO and meningioma: Apart from NF2 alterations in sporadic meningiomas, various oncogenic mutations in KLF4, SMO, TRAF7, PIK3CA, AKT1 and POLR2A are also found to be clinically actionable genetic events in meningiomas (3–5).